ChitogenX Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pierre Laurin
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 16667 Hymus Boulevard Kirkland QC Canada H9H 4R9
- IPO Date
- Oct 6, 2020
- Website
- chitogenx.com
- Similar Companies
- Business
- ChitogenX Inc. is a clinical stage regenerative medicine company specializing in the development of novel therapeutic tissue repair technologies designed to enhance the natural healing processes of body tissues. The company’s core product offerings include its proprietary RESTORE technology platform, a muco-adhesive chitosan-based biopolymer matrix engineered to deliver biologics such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) to accelerate tissue regeneration. Its lead product, Ortho-R, is a chitosan-PRP hybrid biologic implant targeting soft tissue repair in tendons, ligaments, and cartilage, designed for application during surgical procedures to enhance healing rates for musculoskeletal injuries. Additional formulations under development focus on cartilage repair, bone void filling, and osteoarthritis treatment. ChitogenX also pursues broader therapeutic applications of its platform for various tissue repair needs including burn and skin repair. The company operates primarily in Canada, with clinical trial activities ongoing in the United States, focusing initially on orthobiologics applications within the musculoskeletal sector. Founded in 2015 and headquartered in Kirkland, Quebec, ChitogenX was formerly known as Ortho Regenerative Technologies Inc. and rebranded in September 2022 to better reflect its extended product and clinical development scope. Recent strategic developments include a binding letter of intent signed in September 2025 with Oligo Medic Inc., a Canadian biotech firm, to pursue a potential reverse takeover transaction aimed at expanding global commercial capabilities and enhancing clinical development efforts. In late 2023, ChitogenX launched a new burn and skin repair development program targeting an estimated $19 billion market, marking a significant expansion beyond its initial orthopedic focus. The company continues to reduce operating losses while advancing clinical trials and R&D initiatives supported by grants and private placements. ChitogenX’s business model centers on developing high-volume, low-cost orthobiologic products that improve surgical outcomes and reduce healthcare costs. Its technology platform is characterized by enhanced tissue adhesion and prolonged residence time of biologics at injury sites, distinguishing it from standard care treatments. Through ongoing clinical trials, grants, and strategic partnerships, ChitogenX aims to commercialize its products in the US market initially, with plans to broaden therapeutic indications and geographic presence. The company remains publicly traded with ticker CHNXF on the OTCQB exchange, emphasizing both clinical innovation and commercial scalability in regenerative medicine applications.
ChitogenX ends 3Q with improved financial outlook; key milestones achieved
ChitogenX demonstrates ORTHO-R efficacy and osteoarthritis protection in large animal meniscal repair study
ChitogenX targets multi-billion dollar burn and skin repair market
CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM
ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform
ChitogenX receives notice of allowance for key patent in the US and Canada
ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial
ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial
ChitogenX pursuing new strategic development partnerships
ChitogenX highlights milestones achieved in fiscal year
ChitogenX raises $3.9M to advance tissue repair research
ChitogenX announces non-brokered private placement for gross proceeds of $2.5M
ChitogenX obtains $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec
ChitogenX confirms soft-tissue residency properties of its chitosan/PRP-based biopolymer matrix
Chitogenx maintains ‘Outperform' rating as Noble Capital Corp analysts raise price target
ChitogenX looks to raise up to $6.10 million from private placements
ChitogenX earns repeat ‘Outperform' rating from Noble Capital on above-average market opportunity in the regenerative medicine sector
ChitogenX pursues sales of chitosan as a new revenue initiative in fiscal 3Q and restructures balance sheet
ChitogenX successfully completes the initial portion of its US Phase I/II rotator cuff repair clinical trial
ChitogenX announces partnership with California Medical Innovations Institute